Webinars Live
Masterclass Schizophrenia
Changing the Script of Schizophrenia Care
Donderdag 3 juni 2021
Live stream 1: 13:00-14:30 uur
Live stream 2: 19:00-20:30 uur
Live stream 1: 13:00-14:30 uur
Live stream 2: 19:00-20:30 uur
Sprekers
Prof. Christoph Correll
Professor of Child and
Adolescent Psychiatry, Charité
Universitatsmedizin, Berlin,
Germany & Professor of Psychiatry
and Molecular Medicine, Zucker
School of edicine at Hofstra/
Northwell, New York, USA
Prof. John Kane
Professor and Chairman,
Department of Psychiatry, The
Donald and Barbara Zucker, School
of Medicine at Hofstra/Northwell,
New York, USA
Prof. Robin Emsley
Professor in Psychiatry, Sarah
Turoff Endowed Chair in
Schizophrenia Research, Faculty
of Medicine and Health Sciences,
Stellenbosch University, Cape
Town, South Africa
Programma
|
Welcome and introduction to the
Masterclass Prof. Christoph Correll |
|
Reshaping treatment priorities in a
changing world* |
| Q&A with the faculty |
|
Functional recovery in the time of COVID-19 |
| Q&A with the faculty |
|
Working together while being apart |
| Q&A with the faculty |
| Final thoughts from the experts – What can we expect for the future of schizophrenia care? |
* Abilify Maintena (aripiprazole once monthly) data will be presented.
Masterclass Major Depressive Disorder (MDD)
Achieving functional recovery in MDD: The role of anhedonia, emotional blunting & low motivation
Episode 3
Dinsdag 22 juni 2021
Live stream 1: 13:00-14:30 uur
Live stream 2: 19:00-20:30 uur
Live stream 1: 13:00-14:30 uur
Live stream 2: 19:00-20:30 uur
Sprekers
Prof. Roger McIntyre (Chair)
University of Toronto, Toronto,
Canada. Chairman and Executive
Director, Brain and Cognition
Discovery Foundation (BCDF),
Toronto, Canada. Director,
Depression and Bipolar Support
Alliance (DBSA), Chicago,
USA. Head, Mood Disorders
Psychopharmacology Unit
Prof. Andrea Fagiolini
Professor of Psychiatry at the
University of Siena School of
Medicine, Siena, Italy
Programma
|
Welcome & agenda Prof. Roger McIntyre |
|
Anhedonia, emotional blunting and low motivation in MDD: what are the implications for functional recovery? |
| Q&A |
|
Evidence-based decision-making: what do we know about addressing an-hedonia,
emotional blunting and low motivation in clinical practice?* – Latest research data with vortioxetine |
| Panel discussion and Q&A |
* Brintellix (vortioxetine) data will be presented.
|
Welcome & agenda Prof. Roger McIntyre |
|
Anhedonia, emotional blunting and low motivation in MDD: what are the implications for functional recovery? |
| Q&A |
|
Evidence-based decision-making: what do we know about addressing an-hedonia,
emotional blunting and low motivation in clinical practice? – Latest research data with vortioxetine |
| Panel discussion and Q&A |
In this treatment-focused presentation, delegates will learn the importance of early intervention on patient outcomes, as well as how small steps to func-tional recovery can make a big impact on patients’ lives.
In this treatment outcome-focused presentation, delegates will learn more about functional recovery, why it is so important and how it can be achieved. Delegates will also consider how COVID-19 has changed our understanding of functional recovery and what we can learn from it.